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Graphical Abstract
Highlights
d Inhibition of BET proteins reprograms kinome activity in
ovarian cancer cells
d Receptor tyrosine kinase activation overcomes BET
inhibition, causing resistance
d Elevated PI3K/ERK activity stabilizes MYC/FOSL1 proteins in
JQ1-resistant cells
d Co-targeting BET proteins and RTK or PI3K signaling
enhances BET inhibitor therapy
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In Brief
BET inhibitors are currently being
evaluated in clinical trials for a number of
cancers, including ovarian cancer.
Kurimchak et al. demonstrate that BET
inhibitors may have limited success as
single agents in ovarian cancer due to
adaptive kinome reprogramming and will
require combination therapies targeting
kinases and BET bromodomain proteins
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